A dataset comprising 672 tumor specimens collected from 562 patients describes both genetic and functional information about the biology of AML.
Inotuzumab Ozogamicin May Be Efficacious and Safe in Relapsed Pediatric Acute Lymphoblastic Leukemia
The efficacy of inotuzumab ozogamicin in pediatric patients is less understood than in adult patients.
For children with relapsed or refractory B-cell acute lymphoblastic leukemia, tisagenlecleucel was deemed cost-effective, yet long-term outcomes are still uncertain.
For patients in the chronic phase of chronic myeloid leukemia, nilotinib and dasatinib showed comparable efficacy as frontline single agents.
Investigators found that dosing of IgRT in CLL at target levels higher than conventional parameters may offer a therapeutic benefit.
Using a longitudinal parallel-process model, researchers evaluated the impact of physical activity on symptoms, physical activity, and cognitive function in children with ALL undergoing chemotherapy.
Researchers hypothesized that a combination bispecific mAb in B-cell malignancies could offer a treatment option superior to existing monospecific mAbs.
Ibrutinib May Be Effective in Patients With Chronic Lymphocytic Leukemia Who Were Excluded from Clinical Trials
The RESONATE-2 trial excluded certain patients with chronic lymphocytic leukemia, leaving the efficacy and tolerability of ibrutinib in this population unknown.
Findings in an ongoing phase 2 trial demonstrate that a sequential regimen of these agents has significant potential to improve depth of response and outcomes for patients with chronic lymphocytic leukemia.
Albumin-to-fibrinogen ratio may predict poor outcomes in patients with previously untreated chronic lymphocytic leukemia.
Researchers reveal the results of the phase 2 CLL2-BAG trial, which evaluated sequential bendamustine followed by obinutuzumab and venetoclax in patients with CLL.
A single-center retrospective study assessed the effectiveness of serum albumin levels and BMI as prognostic measures in patients with AML.
A population study of a PETALE cohort demonstrated an association between functional health domains and psychological risk in adolescent and adult survivors of cALL.
Early optimal response to TKIs is associated with reductions in treatment failures, poor outcomes, progression of disease, and death.
There is a paucity of data on the use of second-generation tyrosine kinase inhibitors among pediatric patients with chronic-phase chronic myeloid leukemia.
Quizartinib — an investigational FLT3 inhibitor — is the first agent in its class to demonstrate improved overall survival.